Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director Sells $64,080.00 in Stock

Share on StockTwits

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director Joseph Klein III sold 1,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $64.08, for a total value of $64,080.00. Following the completion of the sale, the director now owns 13,683 shares in the company, valued at approximately $876,806.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Joseph Klein III also recently made the following trade(s):

  • On Monday, November 25th, Joseph Klein III sold 812 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $62.90, for a total value of $51,074.80.
  • On Wednesday, November 20th, Joseph Klein III sold 2,000 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $60.00, for a total value of $120,000.00.

NASDAQ IONS traded up $0.82 during trading hours on Wednesday, reaching $65.00. 872,008 shares of the stock traded hands, compared to its average volume of 1,130,595. The stock has a 50 day simple moving average of $58.23 and a two-hundred day simple moving average of $63.02. Ionis Pharmaceuticals Inc has a 1 year low of $48.27 and a 1 year high of $86.58. The company has a debt-to-equity ratio of 0.44, a current ratio of 10.39 and a quick ratio of 10.31. The company has a market cap of $9.00 billion, a price-to-earnings ratio of 21.96, a price-to-earnings-growth ratio of 2.30 and a beta of 1.91.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.18 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.49. Ionis Pharmaceuticals had a return on equity of 36.31% and a net margin of 52.26%. The business had revenue of $168.00 million for the quarter, compared to the consensus estimate of $152.47 million. During the same quarter last year, the business posted ($0.03) earnings per share. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. On average, sell-side analysts forecast that Ionis Pharmaceuticals Inc will post 1.99 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Ionis Pharmaceuticals by 3.1% during the second quarter. Vanguard Group Inc. now owns 12,856,865 shares of the company’s stock valued at $826,311,000 after purchasing an additional 383,350 shares in the last quarter. BlackRock Inc. raised its position in Ionis Pharmaceuticals by 15.5% during the second quarter. BlackRock Inc. now owns 8,802,576 shares of the company’s stock valued at $565,743,000 after purchasing an additional 1,181,004 shares in the last quarter. Invesco Ltd. raised its position in Ionis Pharmaceuticals by 2,754.9% during the second quarter. Invesco Ltd. now owns 2,271,539 shares of the company’s stock valued at $145,992,000 after purchasing an additional 2,191,974 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Ionis Pharmaceuticals during the second quarter valued at about $112,814,000. Finally, Wells Fargo & Company MN grew its stake in shares of Ionis Pharmaceuticals by 5.9% during the second quarter. Wells Fargo & Company MN now owns 1,076,304 shares of the company’s stock valued at $69,174,000 after buying an additional 59,667 shares during the last quarter. Institutional investors and hedge funds own 85.65% of the company’s stock.

A number of brokerages recently issued reports on IONS. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $65.00 price objective on the stock in a research report on Saturday, November 16th. TheStreet downgraded Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Thursday, August 8th. ValuEngine upgraded Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $87.00 price objective on shares of Ionis Pharmaceuticals in a research report on Thursday, November 7th. Finally, Wells Fargo & Co increased their price objective on Ionis Pharmaceuticals from $90.00 to $120.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. Eight analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $75.55.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Further Reading: What is the float in trading stocks?

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.